Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Study to Investigate the Effect of Deferasirox on the Pharmacokinetics of Midazolam

This study has been completed.
Information provided by:
Novartis Identifier:
First received: January 25, 2007
Last updated: November 18, 2009
Last verified: November 2009
This is a study to investigate the pharmacokinetics of deferasirox

Condition Intervention Phase
Drug: Deferasirox
Phase 1

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Pharmacokinetics Study
Intervention Model: Crossover Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: An Open-label, One-sequence Cross-over Study to Investigate the Effect of Deferasirox on the Pharmacokinetics of Midazolam in Healthy Volunteers

Resource links provided by NLM:

Further study details as provided by Novartis:

Primary Outcome Measures:
  • To assess the effect of deferasirox on the pharmacokinetics of midazolam

Secondary Outcome Measures:
  • Safety assessed by adverse events (AEs)

Estimated Enrollment: 22
Study Start Date: July 2006

Ages Eligible for Study:   18 Years to 45 Years   (Adult)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Good health
  • No evidence of iron deficiency
  • Weight between 50 and 100 kg
  • Body Mass Index between 19 and 29 kg/m2

Exclusion Criteria:

  • Use of certain drugs, herbal remedies or nutrients

Other protocol-defined inclusion/exclusion criteria may apply

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00427505

Sponsors and Collaborators
Study Chair: Novartis Novartis
  More Information

Responsible Party: e, Novartis Pharmaceuticals Identifier: NCT00427505     History of Changes
Other Study ID Numbers: CICL670A2126 
Study First Received: January 25, 2007
Last Updated: November 18, 2009
Health Authority: Germany: Federal Institute for Drugs and Medical Devices

Keywords provided by Novartis:
healthy volunteers

Additional relevant MeSH terms:
Adjuvants, Anesthesia
Hypnotics and Sedatives
Central Nervous System Depressants
Physiological Effects of Drugs
Anti-Anxiety Agents
Tranquilizing Agents
Psychotropic Drugs
Anesthetics, Intravenous
Anesthetics, General
GABA Modulators
GABA Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Iron Chelating Agents
Chelating Agents
Sequestering Agents processed this record on October 21, 2016